Difference between revisions of "Paliperidone-Partial agonist"

From Psychiatrienet
Jump to: navigation, search
(Created page with "{{Drugswitch | header= partialagonist | from = Paliperidone | to = Partial agonist | stop = {{StopStand}} | start = {{Startpartial}} | info = {{caveQT}} | view = KlassiekA...")
 
(No difference)

Latest revision as of 13:09, 18 March 2022

Paliperidone
Type Antipsychotic
Group Atypical AP
links
Medscape Paliperidone
EMEA invega
PubChem 115237
PubMed Paliperidone
Kompas (Dutch) Paliperidone
Wikipedia Paliperidone
Partial agonists

Aripiprazole
Brexpiprazole
Cariprazine

Switch medication from Paliperidone to Partial agonist.[1] [2]
Partial agonist is a collection of antipsychotic drugs having similar properties with respect to switching. A switch to member of the 'partial agonist' group from anotherdrug should be read as partial agonist-anotherdrug. Similarly, a switch from a member of the 'partial agonist' group to anotherdrug should be read as anotherdrug-partial agonist.

Nietinrijdenbord.png Stop Paliperidone
  • Day 1-4: approx. 75% of initial dose
  • Day 5-8: approx. 50% of initial dose
  • Day 9-12: approx. 25% of initial dose
  • Day 13: stop
Eenrichtingbord.png Start Partial agonist
  • Day 1-3: start 50% of target dose
  • Day 4-7: target dose
Infobord.png More information
  • During this switch you could monitor ECG, especially in patients prone to QT-conduction problems.
  • There is a possibility of QT interval prolongation.[3]
    KlassiekAP naar partieel1.jpg
Nietinrijdenbord.png — Paliperidone
Eenrichtingbord.png — Partial agonist


  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
  3. Stöllberger C, Huber JO, Finsterer J, Antipsychotic drugs and QT prolongation. Int Clin Psychopharmacol. 2005 Sep;20(5):243-51.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.